<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Oct. 23, 2020 (HealthDay News) — For patients with moderate COVID-19, convalescent plasma does not reduce progression to severe COVID-19 or mortality, according to a study published online Oct. 22 in The BMJ<\/i>.<\/p>\n
Anup Agarwal, M.B.B.S., from the Indian Council of Medical Research in New Delhi, and colleagues conducted an open-label, parallel arm, phase II, randomized, controlled trial at 39 hospitals across India to examine the effectiveness of using convalescent plasma to treat moderate COVID-19. A total of 464 adults admitted to the hospital with confirmed moderate COVID-19 were randomly assigned to either convalescent plasma (two doses transfused 24 hours apart) with best standard of care (235 patients) or best standard of care only (299 patients).<\/p>\n
The researchers found that at 28 days after enrollment, progression to severe disease or all-cause mortality occurred in 19 and 18 percent of patients in the intervention and control arms, respectively (risk difference, 0.008 [95 percent confidence interval, \u22120.062 to 0.078]; risk ratio, 1.04 [95 percent confidence interval, 0.71 to 1.54]).<\/p>\n
“Although our study was underpowered, we did not find any benefit from convalescent plasma being administered within three days of symptom onset in COVID-19,” the authors write.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n